Dr. Ridenour has over two decades of clinical and research experience in etiology, assessment, and clinical research methodologies. One of his foci is developing methods for rigorous analysis of longitudinal, within-person clinical trials using small samples. His recent studies have demonstrated and highlighted the relative strengths and weaknesses of analytic techniques for detecting experimental change within individuals over time, including trajectory analysis and state space modeling. Read his full bio.

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

In the realm of clinical trials, medical and behavioral health care have largely been limited to traditional randomized controlled trial (RCT) designs. RCTs are superb for the acquiring the data for which they were originally designed – efficacy of a treatment in a population. However, for other purposes the utility of RCTs is limited. To illustrate, with greater “precision” in medicine (meaning the application of treatment to more specified types of persons), the RCT requirements for large samples and funding streams generally become less tenable.

Our PersonAlyticsTM idiographic clinical trials (ICTs) approach provides alternatives to RCTs, which are designed to understand within-subject processes that occur in response to a treatment. Under certain conditions (e.g., rare diseases, specific genotypes, early stage drug development, small samples or N=1), ICTs can be used to estimate efficacy. But, perhaps the greatest strength of ICTs is to carefully elucidate how a treatment is affecting individuals as the treatment is delivered and soon thereafter.

Q: What are the products and/or services RTI International offers/develops to address this need? What makes RTI International unique?
A: RTI offers both services and products to help its clients leverage ICT technologies. First, our team has decades of wide-ranging experience in conducting ICTs including drug development for FDA approval, organ transplantation, biosensor-measured outcomes, metabolomics, and psychotherapy (many publications about these studies can be found at: https://personalytics.rti.org/). Second, we provide consultation, collaborative research design, and analytics to support clients’ research and development of treatments and medical devices. Third, we create tailorable software to support patient monitoring and clinical decision-making. One example is Curelator (https://n1-headache.com/), which helps individual patients suffering migraine headaches to identify the triggers/protectors and severity modifiers of his / her migraines; this evidence in turn informs the patient and his / her neurologist of what treatment strategy to pursue in a wholistic and personalized manner. RTI’s software is currently offered as a “white label” product that operates in the background and can be automated for rapid analytics and real-time patient monitoring. RTI is a preeminent non-profit research institution offering expertise across a breadth of health and life sciences, engineering, education and communication sciences, policy, bench science, public health and psychology, environmental sciences, and analytics. Included is RTI Health Solutions, a business unit focused on providing research and advice on clinical, regulatory, market access, and safety programs for pharmaceutical, medical device, and diagnostic companies.
Q: What is your role at RTI International and what excites you about your work?
A: I head the PersonAlytics Team of statisticians and software architects at RTI. As a trained Developmental Behavioral Epidemiologist, I also wear several other hats: NIH-funded researcher, statistician, and developer of medical devices. What gets me out of bed in the morning is the anticipation of making new discoveries that can improve people’s lives. So, by continually improving PersonAlytics services and software, I get to help innovators prepare their treatments and devices to improve people’s health and livelihood.
Q: When thinking about RTI International and the domain RTI International is working in, what are some of the recent breakthroughs that are propelling the field forward and how will they impact healthcare?
A: RTI’s mission is to improve the human condition by turning knowledge into practice, and our researchers apply this mission across a wide breadth of basic and applied sciences. To illustrate the swath of RTI’s research topics, my own first-hand recent collaborations include developing a virtual exercise regimen for patients recovering from heart attack whose health care coverage for physical therapy has run out; identification of marijuana metabolomics that correspond to level of marijuana-induced cognitive dysfunction; validating a biosensor measure of stress based on electrodermal activity levels to test on-the-job stress-reduction interventions; and a clinical trial that is testing a screening, brief intervention and referral to treatment (prevention) for youth at high risk of early-age substance use that can be used during pediatric well-child check-ups. These few examples of RTI’s innovative research are a miniscule sampling of the swath of health care-related work occurring at RTI.
Q: What are the short-term challenges that RTI International and its peers are facing?
A: The most pressing short-term challenge for an organization like RTI is to align with the funding priorities of federal agencies to meet societal needs. For example, within drug abuse research the rise of the opioid epidemic has led to shifts in funding from drug abuse prevention to treatment for heroin addiction and overdose. Another example is that the FDA has recently prioritized speeding up the drug development process to more rapidly get innovative treatments to market. As the research funding landscape evolves, organizations must also evolve to respond with high-quality solutions to the most important scientific and societal challenges we are facing.
Q: Is there anything else you would like to share with the PMWC audience?

A: The RTI International team is looking forward to networking with attendees at PMWC. Precision medicine is at the heart of our PersonAlytics efforts. But, for our methods to move forward and have an impact, we need to collaborate with innovators in health care. We hope to foster those collaborations at PMWC.

Interview with Ralph Snyderman from Duke University

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More

Interview with Ben Solomon from GeneDx

Q: What need is GeneDx addressing?

A: GeneDx was started in 2000 by two NIH scientists with the mission of making genetic testing accessible for patients with rare diseases.

Read More

Interview with Ty Ridenour from RTI International

Q: What need is RTI International addressing?

A: As an independent research institute, RTI is dedicated to improving the human condition. We answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development.

Read More

Interview with Madhuri Hegde, Vice President and Chief Science Officer of PerkinElmer’s Global Laboratory Services

Q: What need is Global Laboratory Services addressing?

A: PerkinElmer Genomics is global (genomics) laboratory service with laboratories in US, India and China, addressing genetic/genomic testing across the globe.

Read More

Interview with Rita R. Colwell from University of Maryland College Park and John Hopkins School of Public Health

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: The research that I am focusing on is understanding the microbiome of the human system and the environment, which means understanding the gut flora and its relationship to health and disease.

Read More

Interview with Dr. Nicholas Dracopoli from Personal Genome Diagnostics

Q: What need is Personal Genome Diagnostics (PGDx) addressing?

A: PGDx is developing standardized, clinical Next Generation Sequencing (NGS) kits to help enable effective treatment decisions for cancer patients.

Read More

Interview with Mohsen Hejrati from Clusterone

Q: What need is Clusterone addressing?

A: AI and machine learning are becoming cornerstone technologies for scientists and engineers, but access to these technologies is still cumbersome.

Read More

VC Investment in Precision Medicine Boomed in Q2 Mega-deals Hitting Record Levels

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Patrick Conway from Blue Cross and Blue Shield of North Carolina

Q: In the past, you served as director of the Center for Medicare and Medicaid Innovation. What are you most proud of accomplishing at CMMI?

A: During my tenure at the Centers for Medicare and Medicaid Services, one of my many roles included serving as the Director of the Center for Medicare and Medicaid Innovation.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!